Ansun BioPharma, Inc. Raises $85 Million in Series A Financing
Represented Ansun BioPharma, Inc. in connection with its $85 million Series A Financing round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. Additional investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment. Ansun intends to use the proceeds to fund a Phase 3 clinical trial of its anti-viral medication, DAS181.
Ansun is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses and has two products in late stage clinical development
We are delighted to secure this strong financial support from some of the most highly regarded biotechnology investment groups in the world,” said Dr. Nancy Chang, the interim CEO of Ansun. “And just as important, if not more important, than their financial support is the depth of knowledge and experience our Board will gain with our new Board members.
